Pulmonary Absorption and Mucociliary Clearance

Separating Pulmonary Input From Mucociliary Removal

A dose deposited in the lung does not necessarily become systemic drug. Part of it may dissolve and cross the lung barrier, while another part is transported toward the throat by mucociliary clearance. These are distinct pathways: pulmonary absorption contributes drug to systemic circulation, whereas mucociliary removal transfers drug out of the lung toward the throat. Treating both as a single “loss” obscures how much drug can contribute to systemic exposure.

The starting amount for this model is the drug deposited in the lung, not the nominal amount emitted by an inhaler. The earlier material on inhaled aerosol deposition as regional lung dose establishes how to obtain a deposited dose. Here, that deposited amount enters a compact two-state model: solid drug dissolves into a dissolved lung pool; drug can leave either pool by mucociliary clearance; and dissolved drug can be absorbed across the lung into systemic circulation.

The Two-State Model and Its Assumptions

Assume first-order dissolution from the solid pool at rate constant \(k_{\mathrm{dis}}\), mucociliary removal from the solid pool at \(k_{mc,s}\), pulmonary absorption from the dissolved pool at \(k_a\), and mucociliary removal from the dissolved pool at \(k_{mc,d}\). Each rate constant is nonnegative and has units of inverse time. The model treats each pool as well mixed, uses constant rates, and assumes that drug removed by mucociliary clearance does not return to the lung or contribute to pulmonary systemic input in this model.

The \(\lambda_s\) and \(\lambda_d\) terms are total exit rates from their respective lung pools. Dissolution is an exit from the solid pool but an input to the dissolved pool; it is not itself systemic absorption. Similarly, mucociliary clearance from either pool adds to \(C_{mc}\), not \(A_p\). This routing is the central distinction the model is designed to preserve.

Solutions and Mass-Balance Justification

The solid-pool equation has the solution \(M_s(t)=D_0e^{-\lambda_s t}\). For \(\lambda_s\ne\lambda_d\), substituting this result into the dissolved-pool equation and solving the resulting linear differential equation gives the following expressions:

The expression for \(A_p(t)\) follows by integrating \(dA_p/dt=k_aM_d(t)\) from zero to \(t\). When \(\lambda_s=\lambda_d=\lambda\), the expressions have finite limits: \(M_d(t)=k_{\mathrm{dis}}D_0t e^{-\lambda t}\) and \(A_p(t)=k_a k_{\mathrm{dis}}D_0[1-e^{-\lambda t}(1+\lambda t)]/\lambda^2\). These equal-rate expressions avoid division by zero and are the appropriate formulas when the total exit rates match.

A useful justification for the whole model is to add the four differential equations. Dissolution cancels because it leaves one lung pool and enters the other. The remaining terms give:

The sum is therefore constant in time and equals its initial value \(D_0\). This mass balance provides both a mathematical check and a practical diagnostic: if the four amounts do not sum to the deposited dose, there is an algebraic error, a unit inconsistency, or an unrepresented pathway.

More generally, when \(\lambda_s>0\) and \(\lambda_d>0\), all material eventually leaves the lung pools. The eventual fractions are:

These fractions sum to one under those conditions: the solid-pool exit fractions satisfy \((k_{\mathrm{dis}}+k_{mc,s})/\lambda_s=1\), and the dissolved-pool exit fractions satisfy \((k_a+k_{mc,d})/\lambda_d=1\). The condition matters. If \(\lambda_s=0\), the initially solid dose remains trapped in the solid pool; if \(\lambda_d=0\), any drug reaching the dissolved pool remains trapped there. In such cases, the eventual absorbed and cleared fractions need not sum to one, and the formulas based on dividing by these exit rates do not apply.

Interpreting Rates, Diagnostics, and Limitations

Dissolution and absorption can each constrain the rate of systemic input. If dissolution is slow relative to the other processes, solid drug is supplied to the dissolved pool gradually. If absorption is slow relative to dissolved-pool clearance, more dissolved drug is removed toward the throat before it can cross the lung barrier. The model keeps these processes separate; the observed systemic input rate is \(k_aM_d(t)\), not the dissolution rate \(k_{\mathrm{dis}}M_s(t)\).

Several checks help identify a poorly implemented or inappropriate model:

• Check mass balance over time. \(M_s+M_d+A_p+C_{mc}\) should equal \(D_0\) at every time, not only at the end of a simulation.
• Check pathway labels and units. \(k_aM_d\) must add to systemic absorption, while \(k_{mc,s}M_s+k_{mc,d}M_d\) must add to throat-directed removal. Each rate multiplied by an amount has units of mass per time.
• Check signs and rate values. With nonnegative rate constants and nonnegative initial amounts, model amounts should not become negative. A negative rate, an increasing amount in the absence of input, or a cumulative amount that decreases signals an error.
• Check for trapped material. If a total exit rate is zero, do not use the all-material-eventually-exits fractions. The model may retain drug in a lung pool indefinitely.
• Check what the initial dose represents. Applying this model to the nominal emitted dose instead of the lung-deposited dose can overstate lung input. Deposition and the present post-deposition processes are separate parts of the dose pathway.

This compact model is an alternative to treating lung input as a single empirical absorption process: it makes dissolution, absorption, and mucociliary removal explicit, so each has a distinct route in the mass balance. It is also simpler than using separate states for multiple lung regions, particle-size classes, or airway and alveolar environments. That simplicity is useful when the available data support only a small number of processes, but it comes with limitations. The model assumes constant first-order rates and homogeneous pools, does not represent spatial transport or changing particle properties, and treats throat-directed material as no longer contributing to pulmonary input. Regional differences or time-varying dissolution may require a more detailed structure. Rate estimates may also be difficult to distinguish from one another using systemic observations alone; predictions should therefore be interpreted in light of the deposited-dose information and the data available to inform the model.